已合成了36个二取代的,单取代的和两个三取代的磺酰胺,并研究了它们在碱中的电离平衡(方案1-3)。许多磺酰胺是新材料。在Hammett和Taft图中,已将每个系列获得的p K a值关联起来。对于邻近氢的电离获得的哈米特ρ值约为。2.3。用于“远程”氢离子化获得的Taftρ*值为1.68。六元环状磺酰胺比其无环类似物的酸性大约高出约2。2.5 p ķ一个单元和五元环sulphamides是CA。4 p K a单元比模型开放链对应单元酸性更高。硫d-轨道参与和环应变被认为是这种“增强酸”作用的可能来源。
Weiss,G.; Schulze,G., Justus Liebigs Annalen der Chemie, 1969, vol. 729, p. 40 - 51
作者:Weiss,G.、Schulze,G.
DOI:——
日期:——
FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF
申请人:SHANGHAI DE NOVO PHARMATECH CO., LTD.
公开号:US20180022752A1
公开(公告)日:2018-01-25
This disclosure is related to a fused-ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the fused ring compound of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in modulating activity of indoleamine 2, 3-dioxygenase (IDO) and/or tryptophan 2, 3-dioxygenase (TDO). This disclosure further provides methods of treating IDO and/or TDO-associated diseases, including cancer, viral infection and autoimmune diseases.